Search PubMed⌕ Search

Biomedical subjects

M A Reilly

Publications and source records attributed to M A Reilly.

At least 19 recordsLinked to original sources

Opposite effects of lithium on proximal and distal caspases of immature and mature primary neurons correlate with earlier paradoxical actions on viability.

To provide an explanation for earlier paradoxical findings of lithium on survival of mature and immature neurons, this study monitors changes in cytosolic caspases in rat cerebellar granule cells (CGC) grown 2-7 days in vitro (DIV), or in murine E-17 cortical neurons. Data show Li+ protects mature 7-DIV CGC parallel to a decrease in proximal and distal caspases but increases levels for immature 2-DIV-CGC or E-17 cortical neurons. Caspases mirror viability based on morphological analyses (dye uptake, phase-contrast, DNA fragmentation), and suggest protection occurs by suppressing activation of a cascade resulting in distal effectors that destroy proteins essential for neuronal survival. Protection was dose-dependent with EC50 3.0 mM and extended to 64 h in K+-serum deprived apoptotic media. Neuronal extracts contain a spectrum of proximal (-2, -8, -9) and distal (-3, -6) caspases sensitive to Li+ on assay with preferred peptide substrates and by immunoblotting. The lack of direct effect on activated cytosols indicates Li+ acts upstream only on intact cells, at sites for recruitment of pivotal procaspases. Alterations of procaspase-9 p46 and membrane-bound cytochrome c (Apaf-1) point to interaction with an intrinsic Mt-mediated pathway as one of the targets. The opposite effects on caspases and viability of immature or embryological neurons point to existence of alternative pathways that alter during neurite outgrowth suggesting the use of Li+ as a probe to unravel events relevant to neurogenesis.

Animals↗

Phenylalanine kinetics are associated with tardive dyskinesia in men but not in women.

RATIONALE: An association between tardive dyskinesia (TD) and severely impaired metabolism of the large neutral amino acid (LNAA), phenylalanine (Phe) was defined in a group of mentally retarded patients. Subsequently, an altered kinetics of Phe was associated with TD in men with schizophrenia based on plasma analyses subsequent to the ingestion of a protein meal. METHODS: In the present study, a standardized oral challenge of pure Phe (100 mg/kg in 170 ml orange juice) was administered to psychiatric patients of both sexes (n = 312), with and without TD after an overnight fast. Plasma LNAA levels were assayed both fasting and 2 h subsequent to the ingestion of the challenge. The extent of the increase in plasma Phe levels 2 h following a standardized challenge is determined by the sum of the kinetic processes of plasma absorption, tissue distribution, metabolism and elimination. RESULTS: The study hypothesis, that TD would be associated with significantly higher post-challenge plasma Phe indices of an absolute plasma Phe level and plasma Phe/LNAA ratio (a brain availability measure), was verified for the study men (n = 209), but not for the study women (n = 103). CONCLUSIONS: The demonstrated altered kinetics of Phe in men with TD indicates a greater availability of Phe to the brain in these men. We suggest that the disorder may be related to the effects of this greater availability. Such effects could be the direct neurotoxic effects of Phe and its metabolites and/or the modulating effects of these compounds on the synthesis of the monoamine neurotransmitters. The fact that TD (Yes/No) group differences in post-challenge plasma Phe indices were not seen for the study women suggests the possibility of a sex difference in the biology of TD that we propose may be reflective of the young age of the study sample.

Absorption↗

Three-dimensional echocardiography improves accuracy and compensates for sonographer inexperience in assessment of left ventricular ejection fraction.

This study was performed to determine whether 3-dimensional echocardiography (3DE) with a magnetic tracking system for image plane localization, which unlike standard 2-dimensional echocardiography (2DE), does not require acquisition of specific image planes or "standard views" for quantitative measurement of left ventricular volume and ejection fraction (EF), could compensate for sonographer inexperience. Eight adults underwent magnetic resonance imaging (MRI) scanning; they also had 2DE and 3DE performed by 2 experienced and 3 novice sonographers. Data were analyzed by a single expert reader blinded to patient and sonographer identity. Linear regression of MRI EF (reference standard) against echocardiographic EF yielded the following results, where RD indicates the residual difference between measured MRI values and those predicted using echocardiographic results: expert 3DE: r = 0.97, RD = 2.4%, and r = 0.96, RD = 2.8%; novice 3DE: r = 0. 83, RD = 5.1%, to r = 0.95, RD = 4.8%; expert 2DE: r = 0.85, RD = 4. 8%, and r = 0.86, RD = 4.9%; and novice 2DE: r = 0.34, RD = 11.7%, to r = 0.69, RD = 6.6%. Comparison of error variances indicated that novices who used 3DE equaled the performance of experts who used 2DE, although experts were always more accurate than novices when both used the same echocardiographic method (3DE vs 3DE, 2DE vs 2DE). In a comparison of methods, 3DE was always superior to 2DE, regardless of sonographer experience. Three-dimensional echocardiography allows even novice sonographers to obtain diagnostic-quality data sets, which they were unable to accomplish with 2DE. These results suggest that scanning with 3DE, combined with remote expert interpretation, may be useful in providing echocardiographic services in regions where they are presently unavailable.

Adult↗

The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry.

The metabolism of ranolazine (RS-43285) or (+)N-(2,6-dimethylphenyl)-4[2-hydroxy-3-(2-methoxyphenoxy)-propyl]-1- piperazine acetamide dihydrochloride was investigated in man using plasma samples obtained from four different clinical studies. The metabolite profiles following single and multiple doses of 342 mg instant release (IR) ranolazine, following multiple doses of 1000 mg sustained release (SR) ranolazine and following dosing with both ranolazine (IR) and a potentially co-administered drug, diltiazem, were compared. Metabolism of ranolazine in man was shown by LC/MS analysis to be extensive with up to seven primary routes of metabolism identified. N-dealkylation by hydrolysis at the piperazine ring produced three metabolites whilst O-demethylation and O-dearylation at the methoxyphenoxy moiety produced a further two compounds. Additionally, hydrolysis of the amide group formed one other species. Oxygenation at various points in the molecule produced a further four metabolites. Direct conjugation of ranolazine with glucuronic acid and with an uncharacterized adduct were also identified as a route of elimination. Ten other biotransformation products were formed as a result of multiple metabolic steps. Conjugation was also associated with the desmethyl metabolite (glucuronide and unidentified conjugates) of hydroxylated ranolazine. In a previous publication (Journal of Chromatography, 1995, accepted for publication) semi-quantitative analyses of pooled plasma from the study where ranolazine was dosed at 1000 mg twice daily showed that of the twelve metabolites studied only four accounted for AUC's in excess of 10% of the ranolazine AUC.

Acetanilides↗

Glutamatergic receptor kinetics are not altered by perinatal exposure to aspartame.

Observation of reduced levels of glutamic acid and aspartic acid in brain of weanling rats exposed perinatally to aspartame prompted a study of the effect of this food additive on glutamatergic receptor kinetics. Aspartame 500 mg/kg/day in drinking water was administered to Sprague-Dawley rats throughout gestation and lactation. Brain was excised from weanlings 20-22 days old, and kinetics of the N-methyl-D-aspartate receptor and total glutamatergic binding in cerebral cortex and hippocampus were found to be unaffected by perinatal exposure to high levels of aspartame. Glutamic acid was decreased in both brain regions studied, and aspartic acid was decreased in hippocampus following perinatal aspartame exposure. These changes were reversible when aspartame administration was terminated. It is concluded that perinatal exposure to high doses of aspartame does not alter glutamatergic neurotransmission in cerebral cortex or hippocampus from weanling rats.

Amino Acids↗

Age-related differences in response programming.

Age-related differential effects on reaction time (RT) performance for movement complexity and response-response (R-R) compatibility were examined in children, adolescents, and young adults. A two-choice RT paradigm involved three different finger responses, and each finger movement response was paired with every other movement response. Movement complexity was manipulated by varying the digits activated and was measured as the mean RT for a particular movement across all choice pairs. R-R compatibility was manipulated by altering the pairing of choice alternatives and was determined by the mean RT comparison for each of the movements according to the paired choice alternative. Simple RTs were also obtained for all finger movement responses for comparison with the RTs achieved in choice situations. Age-related differences were found for both movement complexity and R-R compatibility. Mean RT and response consistency improved with age. Although higher overall speeds were found with age, adolescents were not significantly slower than young adults. Adolescents did, however, make significantly fewer response errors on movements differing in complexity. Bilateral versus unilateral control and number of fingers involved in the task were found to affect both movement complexity and the compatibility between response pairs. The relationship between the alternative and choice response was found to be a robust factor affecting R-R compatibility. Choice responses were significantly slower than simple responses, and the rank ordering of movement responses was identical within the two paradigms.

Adolescent↗

Chronic nicotine administration increases binding of [3H]domperidone in rat nucleus accumbens.

An apparent inverse relationship between smoking and Parkinson's disease prompted an investigation of the effect of chronic nicotine administration on dopaminergic and serotonergic receptors in rat brain. Nicotine, 0.8 mg/kg, was injected once daily, five times per week, for 6 weeks. In nucleus accumbens the Kd for [3H]domperidone was increased 2-4-fold, and the Bmax was increased 1.5-2-fold. No changes were observed in the binding of [3H]domperidone in caudate-putamen or in that of [3H]ketanserin in frontal cortex. It is concluded that chronic nicotine administration may have a suppressant effect on central nervous system release of dopamine that in pre-parkinsonian persons causes an aversion to the effects of smoking.

Animals↗

Intraneuronal dopaminergic action of cocaine and some of its metabolites and analogs.

The present study investigated the actions of cocaine and some of its metabolites and analogs upon the synaptosomal (P2) synthesis and release of dopamine appearing from [14C]phenylalanine. Also examined was the influence of reserpine upon these actions of cocaine. The P2 preparations from the rat caudate nucleus were incubated with the drugs for [14C]phenylalanine and, after filtration, the particulates and medium fractions were analyzed for [14C]dopamine and [14C]phenylalanine. Labelled dopamine in the medium was taken as a measure of its release by any addition of drug. Cocaine, norcocaine and the synthetic cocaine analogs WIN 35428 and WIN 35-065(2) each stimulated both the total (medium plus particulates) formation and the release of dopamine, while benzoylecgonine and ecgonine were without effect. Reserpine inhibited the synthesis and enhanced the release of dopamine. An addition of reserpine blocked the stimulating effect of cocaine, norcocaine, WIN 35428 and WIN 35-065(2) on synthesis and furthermore, these drugs had, in the same experiments, inhibitory effects on the synthesis, additive to the reserpine-induced inhibition. Benzoylecgonine and ecgonine were only weakly inhibitory in the presence of reserpine. Stimulation, rather than additive inhibition, by cocaine was observed in the presence of exogenous dopamine, and amphetamine increased the synthesis in the presence of either reserpine or added dopamine. Pretreatment of rats with reserpine also blocked the stimulation of synthesis by cocaine and WIN 35428. The uptake of labelled substrate was not affected by addition of drug, or by the pretreatment.

Amphetamine↗

Suppression of histamine-induced adrenocorticotropic hormone release by antihistamines and antidepressants.

The antihistaminic activity of many antidepressant drugs is well documented in vitro but has not been investigated as thoroughly in vivo. In the course of an investigation of the roles of H1 and H2 receptors in histamine-induced adrenocorticotropic hormone (ACTH) release in rats, it was observed that several antidepressants were potent inhibitors of this response. Male Sprague-Dawley rats were injected with test drugs and then with histamine or histamine agonists. Serum ACTH concentrations were determined by radioimmunoassay. ACTH secretion was induced by both H1 and H2 receptor stimulation. Histamine-induced ACTH release was markedly attenuated by several H1 antihistamines, whereas the H2 antagonists were not as effective. The antidepressants imipramine, doxepin, mianserin, desipramine and amitriptyline suppressed histamine-induced ACTH release. However, iprindole and the antianxiety agent diazepam were without effect. ACTH release induced by histamine agonists was also diminished by pretreatment with some of these blocking agents.

Adrenocorticotropic Hormone↗

Effect of histamine methylation inhibitors on entry of 14C-histamine into brain.

Pretreatment of mice, rats and guinea pigs with inhibitors of histamine methylation, followed by systemic injection of 14C-histamine, results in a significant increase in brain 14C-histamine relative to controls. It is suggested that the histamine methylating enzyme participates in the blood-brain barrier to histamine.

Amodiaquine↗

Effects of various S-adenosylmethionine preparations on histamine methylation in vitro and in vivo.

To test possible enhancement of in vivo methylation of histamine, mice were injected with S-adenosylmethionine (SAM) of approximately 96% purity. Instead of the expected enhancement, very strong inhibition of methylation was observed. Tests indicated that S-adenosylhomocysteine (SAH) probably was not the inhibitor. Pure SAM, from another source, showed no inhibition of methylation in rats and guinea pigs, and only slight inhibition in mice. Pure SAM was much more effective than the 96% SAM for histamine methylation in vitro. It seems either that injected SAM cannot enter cells containing the histamine methylating enzyme (HME), or that the endogenous supply of SAM is optimal. The inhibitor may be structurally related to SAM, possibly a by-product of SAM synthesis. As it is very effective even in the presence of large amounts of SAM, in pure form it would probably be the most potent inhibitor of histamine methylation available.

Animals↗

Methyl derivatives of histamine; interaction with histamine metabolism.

Several histamine analogs, with ring or side chain methyl groups, were tested for interaction with certain aspects of 14C-histamine metabolism. The physiological catabolite, denoted as 3-methylhistamine under the nomenclature we have adopted, is known to inhibit histamine methylation in vitro and in vivo. At low concentrations, all analogs inhibited histamine methylation by mouse brain homogenates; however 3-methylhistamine was completely ineffective against the highly active enzyme from rat didney, while 2-methylhistamine was most effective. None of the drugs showed a significant effect on in vivo formation of 14C-histamine by mouse stomach. All analogs had a definite effect on the distribution and fate of intravenously injected 14C-histamine. The 2-methyl analog was the strongest in vivo inhibitor of histamine methylation, and 3-methylhistamine next. The side chain N-methylated histamies altered uptake of 14C-histamine in some tissues but inhibited methylation weakly, if at all. Data on blood kidney and urine for 4-methylhistamine were unique, and suggested some effect on tubular reabsorption. 2-methylhistamine may prove to be the inhibitor of choice for in vivo studies on histamine methylation.

Animals↗

Activity changes in mouse brain histidine decarboxylase.

Mice were tested for effects of various factors on histidine decarboxylase of whole brain, or major brain regions. Factors included age, sex, fasting and feeding, season of year, time of day, freezing for various time intervals, and intracerebral injection of protein synthesis inhibitors daily for 2-5 days. In the latter test, 5 day treatment with acetoxycycloheximide reduced brain histidine decarboxylase activity. In one experiment, in which a marked activity increase was observed, brain infection seemed to be the stimulus. Brain enzyme activity in normal mice showed large fluctuations over periods of several months to one year; presumably this is of some physiological significance but the causes are obscure.

Age Factors↗